Novel methods
AssigneeIntra-Cellular Therapies, Inc.
InventorsGretchen SNYDER, Robert DAVIS, Lawrence P. WENNOGLE
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.
Claims29
(canceled)
A method of treating acute depression, comprising administering to a patient in need thereof, a therapeutically effective amount of a Compound of Formula I:
- wherein the Compound of Formula I is in the form of the tosylate salt,
- wherein the method comprises once daily administration of a unit dosage for oral administration in the form of a tablet or capsule comprising the compound of Formula I in tosylate salt form in an amount equivalent to 1 to 60 mg of free base, and a pharmaceutically acceptable diluent or carrier;
- and
- wherein the acute depression is bipolar depression, or depressive episodes associated with bipolar disorder.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.